Quick Answer
LakeShore Biopharma Co., Ltd. reported Total Revenue of $85.67 million for fiscal year 2025.
LakeShore Biopharma Co., Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $85.67M -85.1% |
$573.42M -16.6% |
$687.20M +36.6% |
$502.95M +95.7% |
$257.02M | — |
| Net Income | -$99.98M +76.9% |
-$433.46M -198.0% |
-$145.48M -37.2% |
-$106.00M +44.7% |
-$191.83M | — |
| Diluted EPS | -$5.22 +87.1% |
-$40.54 -72.1% |
-$23.55 -1277.2% |
-$1.71 +44.8% |
-$3.10 | — |
| Total Assets | $190.53M -87.4% |
$1.51B -12.0% |
$1.72B +19.3% |
$1.44B | — | — |
| Long-Term Debt | $23.50M -76.3% |
$98.98M -66.3% |
$293.79M +15.7% |
$253.93M | — | — |
| Stockholders Equity | $69.62M -88.1% |
$585.21M -19.7% |
$728.45M +204.2% |
-$698.97M -37.4% |
-$508.86M +39.9% |
-$847.32M |
| R&D Expense | $20.39M -93.3% |
$302.80M -5.0% |
$318.70M +50.9% |
$211.22M +123.8% |
$94.39M | — |
| Operating Income | -$12.02M +97.3% |
-$445.83M -219.9% |
-$139.38M -17.2% |
-$118.96M +5.5% |
-$125.85M | — |
| Gross Profit | $70.66M -84.5% |
$455.73M -14.6% |
$533.84M +38.3% |
$385.88M +95.5% |
$197.36M | — |
| Shares Outstanding | 20.77M +9.2% |
19.02M -79.6% |
93.06M +50.5% |
61.83M | — | — |
- LakeShore Biopharma Co., Ltd. reported Total Revenue of $85.67 million for fiscal year 2025.
- LakeShore Biopharma Co., Ltd. showed a decrease of -85.1% in Total Revenue compared to the prior fiscal year.
- LakeShore Biopharma Co., Ltd. reported Net Income of -$99.98 million for fiscal year 2025.
- LakeShore Biopharma Co., Ltd. showed an increase of +76.9% in Net Income compared to the prior fiscal year.
- LakeShore Biopharma Co., Ltd. reported Diluted EPS of $5.22 per share (loss) for fiscal year 2025.
- LakeShore Biopharma Co., Ltd. showed an increase of +87.1% in Diluted EPS compared to the prior fiscal year.
- LakeShore Biopharma Co., Ltd. reported Total Assets of $190.53 million for fiscal year 2025.
- LakeShore Biopharma Co., Ltd. showed a decrease of -87.4% in Total Assets compared to the prior fiscal year.
- LakeShore Biopharma Co., Ltd. reported Long-Term Debt of $23.50 million for fiscal year 2025.
- LakeShore Biopharma Co., Ltd. showed a decrease of -76.3% in Long-Term Debt compared to the prior fiscal year.
- LakeShore Biopharma Co., Ltd. reported Stockholders Equity of $69.62 million for fiscal year 2025.
- LakeShore Biopharma Co., Ltd. showed a decrease of -88.1% in Stockholders Equity compared to the prior fiscal year.
- LakeShore Biopharma Co., Ltd. reported R&D Expense of $20.39 million for fiscal year 2025.
- LakeShore Biopharma Co., Ltd. showed a decrease of -93.3% in R&D Expense compared to the prior fiscal year.
- LakeShore Biopharma Co., Ltd. reported Operating Income of -$12.02 million for fiscal year 2025.
- LakeShore Biopharma Co., Ltd. showed an increase of +97.3% in Operating Income compared to the prior fiscal year.
- LakeShore Biopharma Co., Ltd. reported Gross Profit of $70.66 million for fiscal year 2025.
- LakeShore Biopharma Co., Ltd. showed a decrease of -84.5% in Gross Profit compared to the prior fiscal year.
- LakeShore Biopharma Co., Ltd. reported Shares Outstanding of 20.77 million shares for fiscal year 2025.
- LakeShore Biopharma Co., Ltd. showed an increase of +9.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: